论文信息 - Chemoimmunotherapy for relapsed/refractory and progressive 17p13‐deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low‐dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells - 字舞流文

Chemoimmunotherapy for relapsed/refractory and progressive 17p13‐deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low‐dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells

Deborah A. Bowen | T. Witzig | Wenting Wu | B. Laplant | G. Weiner | S. Veeramani | T. Call | B. Link | M. Lindorfer | C. Zent | P. V. Beum | S. Blackwell | D. Viswanatha | Michael J. Conte | R. Taylor | L. Frederick | N. Baig | Margaret A. Lindorfer | Paul V. Beum | Timothy G. Call | Lori A. Frederick | David S. Viswanatha | George J. Weiner | Thomas E. Witzig | R. Taylor | D. Bowen